Cogent Biosciences
COGT
135 hedge funds and large institutions have $886M invested in Cogent Biosciences in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 13 closing their positions.
242% more call options, than puts
Call options by funds: $940K | Put options by funds: $275K
61% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 36
20.62% more ownership
Funds ownership: 85.69% → 106.31% (+21%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
1% less funds holding
Funds holding: 136 → 135 (-1)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
15% less capital invested
Capital invested by funds: $1.05B → $886M (-$162M)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.4M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$9.89M |
| 3 |
BlackRock
New York
|
+$7.94M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$7.5M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$7.03M |
Top Sellers
COGT Hedge Fund Activity: Q3 2023 in Review
135 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2023, worth a combined $886M — down 15% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of COGT and 12 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 58 added.
The largest buyer was Fidelity Investments, adding an estimated $50.4M. The largest seller was Deerfield Management, cutting an estimated $27M.
- 135 institutional investors held Cogent Biosciences (COGT) as of Q3 2023, down from 136 in Q2 2023.
- Funds reported $886M of Cogent Biosciences stock for Q3 2023, down 15% quarter-over-quarter.
- 12 funds opened new Cogent Biosciences positions in Q3 2023 and 13 closed out, a net change of -1 holder.
- The largest Cogent Biosciences buyer in Q3 2023 was Fidelity Investments, an estimated $50.4M added.
- The largest Cogent Biosciences seller in Q3 2023 was Deerfield Management, an estimated $27M sold.
Based on aggregated 13F filings for Q3 2023.